Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France.
J Nucl Med. 2013 Jan;54(1):5-11. doi: 10.2967/jnumed.112.106864. Epub 2012 Dec 4.
The prognosis of patients with locally advanced breast cancer (LABC) remains poor. We prospectively investigated the impact of (18)F-FDG PET/CT at initial staging in this clinical setting and compared PET/CT performance with that of conventional distant work-up.
During 60 mo, consecutive patients with LABC (clinical T4 or N2-N3 disease) underwent (18)F-FDG PET/CT. The yield was assessed in the whole group and separately for noninflammatory and inflammatory cancer. The performance of PET/CT was compared with that of a conventional staging approach including bone scanning, chest radiography, or dedicated CT and abdominopelvic sonography or contrast-enhanced CT.
117 patients with inflammatory (n = 35) or noninflammatory (n = 82) LABC were included. (18)F-FDG PET/CT confirmed N3 nodal involvement in stage IIIC patients and revealed unsuspected N3 nodes (infraclavicular, supraclavicular, or internal mammary) in 32 additional patients. Distant metastases were visualized on PET/CT in 43 patients (46% of patients with inflammatory carcinoma and 33% of those with noninflammatory LABC). Overall, (18)F-FDG PET/CT changed the clinical stage in 61 patients (52%). Unguided conventional imaging detected metastases in only 28 of the 43 patients classified M1 with PET/CT (65%). (18)F-FDG PET/CT outperformed conventional imaging for bone metastases, distant lymph nodes, and liver metastases, whereas CT was more sensitive for lung metastases. The accuracy in diagnosing bone lesions was 89.7% for planar bone scanning versus 98.3% for (18)F-FDG PET/CT. The accuracy in diagnosing lung metastases was 98.3% for dedicated CT versus 97.4% for (18)F-FDG PET/CT.
(18)F-FDG PET/CT had the advantage of allowing chest, abdomen and bone to be examined in a single session. Almost all distant lesions detected by conventional imaging were depicted with PET/CT, which also showed additional lesions.
在初始分期中前瞻性研究局部晚期乳腺癌(LABC)患者¹⁸F-FDG PET/CT 的影响,并将其与传统的远处检查方法进行比较。
在 60 个月期间,连续入组 LABC(临床 T4 或 N2-N3 疾病)患者行¹⁸F-FDG PET/CT。评估整组患者和非炎性及炎性癌患者的检出率。比较 PET/CT 与包括骨扫描、胸部 X 线摄影或专用 CT 以及腹盆腔超声或增强 CT 的常规分期方法的性能。
纳入 117 例炎性(n=35)或非炎性(n=82)LABC 患者。¹⁸F-FDG PET/CT 证实ⅡIC 期患者存在 N3 淋巴结受累,并在另外 32 例患者中发现了未被怀疑的 N3 淋巴结(锁骨下、锁骨上或内乳)。43 例患者(炎性癌患者的 46%和非炎性 LABC 患者的 33%)在 PET/CT 上显示远处转移。总的来说,¹⁸F-FDG PET/CT 改变了 61 例患者(52%)的临床分期。未行引导的常规影像学检查仅在 43 例 PET/CT 分类为 M1 的患者中发现 28 例转移(65%)。¹⁸F-FDG PET/CT 在骨转移、远处淋巴结和肝转移方面优于常规影像学检查,而 CT 对肺转移更敏感。在诊断骨病变方面,平面骨扫描的准确率为 89.7%,¹⁸F-FDG PET/CT 为 98.3%。在诊断肺转移方面,专用 CT 的准确率为 98.3%,¹⁸F-FDG PET/CT 为 97.4%。
¹⁸F-FDG PET/CT 的优势在于可以在一次检查中同时检查胸部、腹部和骨骼。几乎所有通过常规影像学检查发现的远处病变都在 PET/CT 上显示,且 PET/CT 还显示了其他病变。